Research-use-only educational overview. This article is not medical advice and is not a recommendation to use, take, or buy any compound.
Search “best peptides for cognitive function and focus” and you will find confident rankings and shopping lists. This page takes a different approach. Instead of naming a “winner,” it looks at the three peptides people most often research and discuss in this context — Semax, Selank and Dihexa — and asks a harder question: what does the published evidence actually show?
One distinction runs through everything below. “Most studied” or “most discussed” is not the same as “proven to work,” and neither is the same as “right for you.” For scale, GLP-1 receptor agonists have large, replicated human randomized controlled trials behind their effects on body weight. The cognitive peptides here are nowhere near that standard — their evidence ranges from small human studies to animal-only data. Nothing on this page is a directive to use any compound. All three are sold for research use only, none is an approved treatment for cognition or focus, and this is educational information, not medical advice.
Comparison at a glance
| Peptide | What it’s studied for (re: cognitive function & focus) | Evidence tier | Key caveat |
|---|---|---|---|
| Semax | Neuroprotection and recovery after ischemic stroke; neurotrophin/BDNF modulation; popularly described as a “nootropic” | Preclinical (animal) plus limited, low-quality human use in Russia; no rigorous Western RCTs | Human cognitive-enhancement data in healthy people is essentially absent; evidence base is largely Russian-language |
| Selank | Anxiety reduction (which can indirectly affect attention); memory/attention in animal models | One small human RCT for anxiety; cognitive/focus effects preclinical or indirect | The human trial targeted anxiety, not focus; sold as an unregulated “supplement,” safety poorly characterized |
| Dihexa | Synapse formation and memory-task performance in animal models via the HGF/c-Met system | Preclinical (animal) only | No human trials; a foundational mechanistic paper was later retracted |
Semax
Semax is a synthetic peptide based on a fragment of adrenocorticotropic hormone (ACTH 4–7) joined to a Pro-Gly-Pro tail. In Russia it is registered and used clinically as a neuroprotective agent for ischemic stroke and is popularly marketed as a “nootropic.” According to PubMed, the English-language research is dominated by animal models: in rat models of cerebral ischemia, Semax modulates neurotrophin signaling and dampens inflammatory and cell-death pathways (Sudarkina et al., 2021; Stavchansky et al., 2022). What is largely missing is rigorous, peer-reviewed human evidence — particularly placebo-controlled trials of cognition or focus in healthy adults. The honest read is that Semax is mechanistically interesting but that cognitive-enhancement claims in healthy people are not established. You can review the figures discussed in the research community on our Semax dosage reference.
Selank
Selank is a synthetic analog of the immune peptide tuftsin, developed in Russia primarily as an anxiolytic. It has the most direct human data of the three: a Russian comparative randomized trial in 62 patients with generalized anxiety disorder and neurasthenia reported anxiolytic effects comparable to the benzodiazepine medazepam, alongside mild anti-asthenic and stimulating effects (Zozulia et al., 2008). Crucially, that trial studied anxiety, not focus or memory — any effect on concentration would be indirect (less anxiety can make attention easier). Direct cognitive effects have mainly appeared in animals, for example rats in which Selank blunted alcohol-related memory and attention impairment while modulating BDNF (Kolik et al., 2019). A clinical-pharmacology review also cautions that Selank is poorly studied and is sold to US consumers as an unregulated “dietary supplement” (Doyno & White, 2021). Our Selank dosage reference documents how it is typically handled in research settings.
Dihexa
Dihexa is a small-molecule angiotensin IV analog engineered to cross the blood–brain barrier and promote synapse formation. In animal studies it has been reported to improve performance on memory tasks and to drive synaptogenesis through the hepatocyte growth factor (HGF)/c-Met system (Wright et al., 2015, review). This is the least human-validated compound on the page: there are no published clinical trials of dihexa itself for cognition, and — importantly for honesty — a key 2014 paper underpinning its procognitive mechanism was subsequently retracted (Benoist et al., 2014, later retracted). So while its laboratory potency looks striking, dihexa remains preclinical and its safety in humans is essentially uncharacterized. Our Dihexa dosage reference lists the numbers cited in the research literature, for documentation only.
What the evidence actually supports
Ranked by strength of human evidence rather than by hype:
- Selank has the most direct human data — but for anxiety, not focus. Its attention/memory benefits remain preclinical or indirect.
- Semax has real-world clinical use in Russia and a substantial mechanistic literature, yet almost no rigorous, English-language human trials for cognition in healthy people.
- Dihexa is animal-only, carries a retraction in its foundational mechanistic work, and has no human trials.
The bottom line for “cognitive function and focus” specifically: none of the three has robust, replicated human randomized-controlled-trial evidence of enhancement in healthy adults. Anyone presenting a clear “best” is going beyond what the data supports. The strongest evidence here is for a neighboring outcome (anxiety), and the flashiest mechanistic story (Dihexa) is also the least validated in people.
Important limitations
- Research use only. Semax, Selank and Dihexa are not approved by the FDA as treatments for cognition or focus, and are not approved cognitive-enhancement therapies anywhere in mainstream regulatory use.
- The evidence is thin. Much of it is animal data or small, older, non-English human studies, and one key dihexa paper was retracted — a reason for caution, not confidence.
- Individual results and safety are unknown. Purity, long-term safety, dosing, and interactions are poorly characterized, and unregulated “supplement” sourcing adds further risk.
- This is not medical advice. Decisions about your health belong with a qualified healthcare professional who knows your history.
If you are studying reconstitution and concentration math for research documentation, our peptide dosage calculator can help you check the numbers. It is an educational tool, not a prescription or an endorsement of use.
FAQ
Which peptide is “best” for focus?
No peptide has been proven “best” for focus in healthy people. Selank has the most direct human evidence, but it was studied for anxiety rather than focus, while Semax and Dihexa are largely preclinical for cognition. “Most studied” is not the same as “proven for you.”
Are these approved or safe for cognitive enhancement?
No. None is an approved cognitive-enhancement therapy, and all are sold for research use only. Their long-term safety in humans is not well characterized, and at least one is commonly sold as an unregulated supplement. Speak with a qualified healthcare professional before making any health decision.
Does animal or mechanistic evidence mean it works in people?
Not on its own. Many compounds that improve memory in rodents show no benefit in human trials, and mechanistic findings can later be overturned — as the retracted dihexa paper illustrates. Animal and mechanistic data are a reason for further study, not proof of a human effect.
Educational, research-use-only information. Not medical advice, not a diagnosis, and not a recommendation to use any compound. Consult a qualified healthcare professional.
